TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03790878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Training in a mindful breathing skill that reduces emotional distress

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habituation
Description: An exposure procedure that reduces emotional distress through habituation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No emotion regulation intervention, placebo
Study: NCT03353155

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CareHub
Study: NCT03644784

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized protocol for assessing aortic regurgitation using videodensitometry
Description: Standardized protocol for assessing aortic regurgitation using videodensitometry
Study: NCT00192296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 3 mg/kg
Description: MEDI-528 (3 mg/kg) administered as a single, IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 9 mg/kg
Description: MEDI-528 (9 mg/kg) administered as a single, IV dose
Study: NCT03880279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-CD19
Description: Dose-escalating cohorts plus expansion groups
Study: NCT04437693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
Study: NCT01999075

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Volume Recruitment (LVR)
Description: LVR will be used twice per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Treatment
Description: This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
Study: NCT04093219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: use of IV tylenol for pain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
Study: NCT03842189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: Participants will receive once weekly intravenous (IV) infusions of M281
Study: NCT02681328

Intervention type: OTHER
Intervention: Afirma GEC
Description: Afirma GEC molecular test on collected thyroid tissue
Study: NCT01478672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Health Coaching and Life-long Monitoring
Description: Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
Study: NCT02681328

Intervention type: OTHER
Intervention: ThyroSeq v.2
Description: ThyroSeq v.2 molecular test on collected thyroid tissue

Intervention type: OTHER
Intervention: Afirma GSC
Description: Afirma GSC molecular test on collected thyroid tissue

Intervention type: OTHER
Intervention: ThyroSeq v.3
Description: ThyroSeq v.3 molecular test on collected thyroid tissue
Study: NCT00531713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triiodothyronine
Description: 50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
Study: NCT01901770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive HPV vaccination educational materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive influenza vaccination educational materials
Study: NCT03156634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PALS
Description: PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WebMD
Description: WebMD is an internet based health information source.
Study: NCT01899456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter-based renal denervation
Study: NCT02601534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero-time Exercise
Description: a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Eating
Description: a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
Study: NCT00542438

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Recall
Description: Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Environmental Assessments
Description: Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
Study: NCT04226547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)
Description: Implantation of an Amplatzer Amulet left atrial appendage occluder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Vitamin K Oral Antagonists
Description: Initiation or continuation of a NOAC drug
Study: NCT04455308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample collection
Description: 10mL blood sample

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biological sample collection
Description: 10mL blood sample
Study: NCT01686880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirsphere trans-arterial radioembolization
Description: Patients will receive Sirsphere trans-arterial radioembolization before surgery
Study: NCT04461743

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, regular therapy

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, regular therapy
Study: NCT04437693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
Study: NCT00240006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shared Solutions® plus MS Center v. Shared Solutions®
Description: Copaxone
Study: NCT00446069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulphate
Description: Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulphate
Description: Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
Study: NCT01910987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib (optimized retreatment)
Description: Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
Study: NCT02247336

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family health history platform (MeTree)
Description: Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family health history platform (MeTree)
Description: Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
Study: NCT04642820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of Methamphetamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of Methamphetamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT01910987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone (optimized retreatment)
Description: Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6

Intervention type: DRUG
Group type: OTHER
Intervention: bortezomib (standard retreatment)
Description: Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone (standard retreatment)
Description: Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
Study: NCT00595738

Intervention type: OTHER
Intervention: Standard of care therapy for severe decompensated heart failure
Description: Standard of care therapy for severe decompensated heart failure
Study: NCT03834766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMPH ER Tab 5, 10, 15 and 20 mg
Description: Amphetamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Description: Placebo
Study: NCT02655510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-652
Description: Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
Study: NCT04599348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HRG 80 Red Ginseng
Description: A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
Study: NCT04455191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thawing Embryos in Advance
Description: Thaw Embryos one day in Advance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thawing Embryos on the Day of Transfer
Description: Thaw Embryos on the morning of transfer day.
Study: NCT04778462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave and conventional treament
Description: Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band will be applied as low energy 2 sessions per week for 2 weeks The will be used as a radial type of shock wave therapy.~Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high pain threshold ultrasound and conventional treatment for myofascial pain syndrome trigger points
Description: will be applied in continuous mode, with the probe placed directly on the TrP and held motionless. To elicit threshold pain, the US probe will be kept static on the TrP. Intensity gradually will be increased to the level of maximum pain the patient could bear. It will be kept at that level for 3 to 4 seconds, then will be reduced to the half-intensity level for another 15 seconds. This procedure was repeated 3 times.the intensity of US will be dependent on the patient's level of pain. intensity will be applied in the range of 0.5 to 2.0 Watt per/cm2. Patients continually report their pain level and its localization and nature High-power pain threshold US will be applied 4 times, with a 3-day interval 2 sessions per week for 2 weeks .~1)Isometric neck extensor exercise2)Isometric neck flexor exercise3)Isometric neck side bending muscle exercise,Stretching exercise:Passive stretching for the neck extensor muscles ,stretching of the neck side-bending muscles,Ischemic compression

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment for myofascial pain trigger point
Description: Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression
Study: NCT04275921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI analysis using TWIST and HASTE

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI analysis using TWIST and HASTE

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 4D MRI
Description: 4D MRI alongside 4D CT in lung cancer
Study: NCT01243996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
Study: NCT03641898

Intervention type: PROCEDURE
Intervention: FFR-guided PCI
Description: After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or \>90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR \>0.80 are defined as FNLs and should result in deferral of PCI.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular ultrasound
Description: After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
Study: NCT04240483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections (ISWI) group
Description: ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intracutaneous dry injections (IDI) group
Description: Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
Study: NCT02497833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: retinoic acid
Description: During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
Study: NCT03291457

Intervention type: DRUG
Intervention: Tocilizumab
Description: For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Glucocorticoid Agent
Description: Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
Study: NCT02302573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: contast-enhanced ultrasound with sonovue
Description: contast-enhanced ultrasound with sonovue
Study: NCT00710203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodesiccation
Description: A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: A fourth lesion will not be treated and will serve as a control.
Study: NCT04586647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss.
Description: The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
Study: NCT04642820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT03896217

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
Study: NCT04275921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 4D MRI
Description: 4D MRI alongside 4D CT in lung cancer
Study: NCT03282721

Intervention type: PROCEDURE
Intervention: precise location of commissure
Study: NCT02783729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study: NCT00309075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist)
Description: Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Study: NCT01075139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: 30 minute one-on-one meeting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational information
Description: Educational handouts/brochures